Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Mehta · SciRah

Researcher profile · Semantic Scholar

R. Mehta

Share profile

R. Mehta — researcher profile on SciRah

h-index: 17
Works: 68
Citations: 1,333

Most-cited papers

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
J. Donohue, M. R. Maleki-Yazdi, S. Kilbride, R. Mehta +2 more
2013Respiratory Medicine288 citations Open access
Semantic Scholar
Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
B. Celli, G. Crater, S. Kilbride, R. Mehta +3 more
2014Chest164 citations
Semantic Scholar
Umeclidinium in patients with COPD: a randomised, placebo-controlled study
R. Trivedi, N. Richard, R. Mehta, A. Church
2013European Respiratory Journal99 citations Open access
Semantic Scholar
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
J. Donohue, A. Anzueto, Jean Brooks, R. Mehta +2 more
2012Respiratory Medicine70 citations Open access
Semantic Scholar
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.
M. Decramer, F. Maltais, G. Feldman, Jean Brooks +3 more
2013Respiratory Physiology & Neurobiology60 citations
Semantic Scholar
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
G. Feldman, R. Walker, Jean Brooks, R. Mehta +1 more
2012Pulmonary Pharmacology & Therapeutics48 citations
Semantic Scholar
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial
Dennis L. Kelleher, R. Mehta, Bernadette M. Jean-Francois, A. Preece +3 more
2012PLoS ONE47 citations Open access
Semantic Scholar
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
R. Mehta, Dennis L. Kelleher, A. Preece, S. Hughes +1 more
2013International Journal of COPD41 citations Open access
Semantic Scholar
Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
N. Goyal, M. Beerahee, C. Kalberg, A. Church +2 more
2014Clinical Pharmacokinetics33 citations
Semantic Scholar
Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies.
R. Tal-Singer, A. Cahn, R. Mehta, A. Preece +3 more
2013European Journal of Pharmacology33 citations
Semantic Scholar
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
A. Church, M. Beerahee, Jean Brooks, R. Mehta +1 more
2014BMC Pulmonary Medicine31 citations Open access
Semantic Scholar
Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
P. Qaqundah, R. Sugerman, E. Ceruti, J. Máspero +5 more
2006Jornal de Pediatria28 citations
Semantic Scholar
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies
A. Cahn, R. Tal-Singer, I. Pouliquen, R. Mehta +4 more
2013Clinical drug investigation25 citations
Semantic Scholar
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
N. Brealey, Ashutosh Gupta, J. Renaux, R. Mehta +2 more
2015International journal of clinical pharmacology and therapeutics24 citations Open access
Semantic Scholar
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Dennis L. Kelleher, L. Tombs, A. Preece, N. Brealey +1 more
2014Pulmonary Pharmacology & Therapeutics24 citations
Semantic Scholar
Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
Kathryn V. Blake, R. Mehta, T. Spencer, Robert L. Kunka +1 more
2011European Respiratory Journal21 citations Open access
Semantic Scholar
Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
R. Kempsford, M. Handel, R. Mehta, Mariza De Silva +1 more
2005Respiratory Medicine21 citations Open access
Semantic Scholar
Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
P. Daley-Yates, R. Mehta, Robert H Chan, Simona X Despa +1 more
2014Journal of Aerosol Medicine17 citations
Semantic Scholar
Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial
Chao-Ying Hu, Jingying Jia, K. Dong, Linda Luo +6 more
2015PLoS ONE15 citations Open access
Semantic Scholar
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
R. Mehta, K. Hardes, Dennis L. Kelleher, A. Preece +2 more
2014Clinical Therapeutics15 citations
Semantic Scholar
Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Inhaled Once-Daily Umeclidinium in Healthy Adults Deficient in CYP2D6 Activity: A Double-Blind, Randomized Clinical Trial
A. Cahn, R. Mehta, A. Preece, James Blowers +1 more
2013Clinical drug investigation15 citations
Semantic Scholar
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults
R. Mehta, K. Hardes, A. Cahn, A. Newlands +4 more
201115 citations
Semantic Scholar
Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease.
D. Johnson, R. Joshi, R. Mehta, A. R. Cunnington
1986European journal of respiratory diseases. Supplement15 citations
Semantic Scholar
Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
R. Mehta, K. Hardes, N. Brealey, L. Tombs +2 more
2014International Journal of COPD13 citations Open access
Semantic Scholar
Dose response of umeclidinium administered once or twice daily in patients with COPD: A pooled analysis of two randomized, double‐blind, placebo‐controlled studies
J. Donohue, C. Kalberg, Palvi Shah, M. Beerahee +3 more
2014Journal of clinical pharmacology12 citations
Semantic Scholar
Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients
J. Beier, J. van Noord, A. Deans, Jean Brooks +4 more
2012International Journal of COPD12 citations Open access
Semantic Scholar
Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults
Dennis L. Kelleher, Steve Hughes, R. Mehta, L. Tombs +2 more
201211 citations
Semantic Scholar
Safety And Tolerability Of The GSK573719/Vilanterol Combination In Patients With COPD
G. Feldman, R. Walker, Jean Brooks, R. Mehta +1 more
2012Asian Test Symposium11 citations
Semantic Scholar
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
A. Cahn, Rosalind Lovick, A. Newlands, A. Deans +5 more
201111 citations
Semantic Scholar
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
R. Mehta, Allen Wolstenholme, Kristin Di Lullo, Caifeng Fu +6 more
2018Antimicrobial Agents and Chemotherapy8 citations Open access
Semantic Scholar
Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler
A. Moore, Kylie Riddell, Shashidhar Joshi, Robert H Chan +1 more
2017Journal of Aerosol Medicine8 citations Open access
Semantic Scholar
Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
R. Mehta, P. Daley-Yates, K. Jenkins, Joseph Bianco +3 more
2014Pulmonary Pharmacology & Therapeutics8 citations
Semantic Scholar
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD
R. Mehta, A. Newlands, Dennis L. Kelleher, A. Preece +2 more
2011European Respiratory Journal8 citations
Semantic Scholar
Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK)
Dennis L. Kelleher, K. Hardes, N. Brealey, L. Tombs +2 more
20137 citations
Semantic Scholar
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
R. Mehta, C. Farrell, S. Hayes, Ruby Birk +2 more
2019Clinical Pharmacokinetics6 citations Open access
Semantic Scholar
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
R. Mehta, E. Pefani, M. Beerahee, N. Brealey +4 more
2018Journal of clinical pharmacology6 citations Open access
Semantic Scholar
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
P. Daley-Yates, A. Deans, R. Mehta, A. Sousa
2022Pulmonary Pharmacology & Therapeutics5 citations
Semantic Scholar
Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
R. Mehta, Michelle L. Green, B. Patel, J. Wagg
2016Journal of Pharmacokinetics and Pharmacodynamics5 citations
Semantic Scholar
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)
Dennis L. Kelleher, A. Preece, R. Mehta, A. Donald +3 more
2011European Respiratory Journal5 citations
Semantic Scholar
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies
R. Mehta, Chakradhar V. Lagishetty, Konstantinos Angelis, A. Aylott +7 more
2023British Journal of Clinical Pharmacology4 citations Open access
Semantic Scholar
Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler
R. Mehta, Kylie Riddell, Ashutosh Gupta, M. D. Louey +1 more
2015Clinical drug investigation4 citations
Semantic Scholar
Umeclidinium (GSK573719) dose response and dosing interval in COPD
A. Church, M. Beerahee, Jean Brooks, R. Mehta +1 more
20124 citations
Semantic Scholar
The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
R. Mehta, Joseph Piscitelli, Allen Wolstenholme, Caifeng Fu +3 more
2020Clinical Pharmacology : Advances and Applications3 citations Open access
Semantic Scholar
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
N. Brealey, Ashutosh Gupta, J. Renaux, R. Mehta +2 more
2016International journal of clinical pharmacology and therapeutics3 citations
Semantic Scholar
S4 Implications of guidance in scotland on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis
Cea Hartmann, C. Gait, N. Gunsoy, R. Mehta +1 more
20163 citations Open access
Semantic Scholar
Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK)
R. Mehta, K. Hardes, Dennis L. Kelleher, A. Preece +2 more
20133 citations
Semantic Scholar
Efficacy and safety of the long‐acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD
E. Bateman, G. Feldman, S. Kilbride, Jean Brooks +4 more
2012Clinical Respiratory Journal3 citations
Semantic Scholar
Safety, Tolerability And Pharmacokinetics (PK) Of Single And Repeat Doses Of GSK573719 In Healthy Japanese Subjects
N. Nakahara, Naoki Takahashi, Dennis L. Kelleher, R. Mehta
2012Asian Test Symposium3 citations
Semantic Scholar
Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD
J. Donohue, A. Anzueto, Jean Brooks, R. Mehta +2 more
20113 citations Open access
Semantic Scholar
Systemic Exposure and Urinary Cortisol Effects of Fluticasone Propionate Formulated With Hydrofluoroalkane in 4‐ to 11‐Year‐Olds With Asthma
Kenneth T. Kim, H. Milgrom, Y. Yoon, A. Levy +8 more
2008Journal of clinical pharmacology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Crater×14
Invite
G. Crater — researcher profile on SciRah
Dennis L. Kelleher×14
Invite
Dennis L. Kelleher — researcher profile on SciRah
A. Preece×14
Invite
A. Preece — researcher profile on SciRah
Jean Brooks×9
Invite
Jean Brooks — researcher profile on SciRah

×9

Invite

A. Cahn — researcher profile on SciRah

Invite

A. Church — researcher profile on SciRah

Invite

N. Brealey — researcher profile on SciRah

Invite

K. Hardes — researcher profile on SciRah

Invite

C. Kalberg — researcher profile on SciRah

Invite

L. Tombs — researcher profile on SciRah

Invite

M. Beerahee — researcher profile on SciRah

Invite

J. Donohue — researcher profile on SciRah